Gerresheimer Pitches 5 ml Autoinjector Concept as Goldman and BofA Trim Stakes
Published on 11/18/2026 at 02:31 | Editorial boerse-global.deGerresheimer used the back end of last week to roll out a concept version of its Gx Inbeneo cartridge autoinjector platform for 5 ml volumes, a design the company says is aimed at highly viscous or large-volume biologic formulations. The Düsseldorf-based group was careful to label the reveal a concept rather than a launched product.
The product news came alongside a fresh commitment to Dualis, whose APS software Ganttplan will continue to run alongside SAP in Gerresheimer's injection-moulding operations following a re-tender of its production management infrastructure. Media reports framed the decision as a continuation of an existing planning stack rather than a new build.
Diabetes Push and Needle Refinements
Saturday's calendar slot, tied to World Diabetes Day, saw the company put its drug-delivery portfolio for diabetes and obesity therapies front and centre, stating that it turns out hundreds of millions of pens every year. That figure refers specifically to annual pen output.
The 5 ml concept follows disclosure on 6 November of an optimised cannula profile for the Gx RTF Elite SIN Glass Syringe platform. Gerresheimer lists lower tissue resistance and reduced coring and perforation risk among the development goals for the needle design.
Should investors sell immediately? Or is it worth buying Gerresheimer?
Ownership Filings Move in the Other Direction
On the shareholder register, Goldman Sachs reported a decline in its attributed voting rights including financial instruments. Stock-based rights accounted for 9.41% in the filing, with instruments adding a further 2.48%. The US bank had already flagged a reduction in its aggregate position relative to its prior disclosure for 2 November, when the earlier total stood at 15.65%. That same notification named Nationale-Nederlanden Levenverzekering Maatschappij N.V. as a direct shareholder holding at least 3% of voting rights.
Bank of America also disclosed a smaller overall position, at 4.92% including instruments, down from 5.07% previously.
Deutsche Bank Lifts Its Target
Deutsche Bank Research moved the other way on valuation, raising its price target to EUR 28 from EUR 26 on 4 November while keeping its "Hold" rating unchanged.
Gerresheimer at a turning point? This analysis reveals what investors need to know now.
Investors looking further ahead have the half-year financial report pencilled in for late November 2026, per the company's financial calendar. In the meantime, Gerresheimer hosted a delegation from North Macedonia led by Prime Minister Hristijan Mickoski at its Düsseldorf headquarters on 5 November, using the visit to put its investment volume in the country at roughly EUR 150 million.
Ad
Gerresheimer Stock: New Analysis - 18 November
Fresh Gerresheimer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
